GPR152

Across TCGA pan-cancer cohorts, GPR152 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GPR152 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher GPR152 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GPR152 expression acts as an unfavorable survival marker, although some lineages such as SKCM and COAD show a favorable association.

BLCA, ESCA, and LIHC are the cancer types where GPR152 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.130	0.720	<.001	48	view →
ESCA	OS	Median	II,III,IV	0.130	0.703	<.001	24	view →
LIHC	DFS	Median	II,III,IV	0.080	0.427	.019	6	view →
SKCM	DFS	Median	III,IV	0.772	0.202	.036	4	view →
COAD	DFS	Median	II,III,IV	1.000	0.649	.029	2	view →
LUAD	DFS	Median	II,III,IV	1.000	0.252	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GPR152–BLCA (OS)

Open the BLCA breakdown →